Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
Gene editing: overhyped or unstoppable tide?
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Spotlight – Travere trips up but others are following in rare kidney disease
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Novartis stays focused
No big deals needed, executives insist, but a pipeline purge continues and analysts warn of a growth problem.
Finding the big spenders beyond big pharma
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
Big pharma holds steady on research spending
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.
Big pharma’s biggest spenders revealed: 2022 edition
Pfizer’s buying spree propels it up the rankings, while Lilly continues to turn (relatively) small spend into big value.
